Ariana Pharma is transforming the way drugs are developed. Key challenges facing clinical development in early phases is to select optimal patients, indications and endpoints, and doing so in data-driven mode. This hurdle is even higher considering small number of patients in early trials characterized by a large number of parameters. Combining advanced Artificial Intelligence (AI) technology, clinical development, and regulatory expertise, Ariana optimizes drug development with increased probability of success compared to traditional analytic methods.
Ariana KEM® explainable Artificial Intelligence (xAI) technology systematically explores any type of clinical data to produce more effective biomarker signatures for precision medicine, optimize clinical endpoints, and identify potential synergistic therapies. Clinical datasets can be strengthened using Real World Evidence (RWE). Ariana’s multidisciplinary drug development team leverages the FDA-assessed xAI platform to translate findings into innovative clinical development plans and regulatory approvals. Our xAI platform is used by biopharmaceutical and biotech around the world, with a growing number of successful therapeutic development programs across multiple therapeutic indications.
Founded in 2003 as a spin-off of Pasteur Institute in Paris, the company operates a subsidiary in the United States. To learn more, visit www.arianapharma.com
, follow us on LinkedIn